Skip to content
Israel Biotech Fund
  • About
  • Strategy
  • Portfolio
  • Team
  • Advisors
  • Partnerships
  • News
  • Contact
  • Investors
◀︎ All News

Big Year for Israeli Tissue Agnostic Company Ayala

May 16th, 2019 by IBF

Ayala is looking to lead the way for the country’s burgeoning biotech sector and take its gamma secretase inhibitors all the way through to Phase III.

Categories Uncategorized
Ayala entered a license agreement with Novartis
Novartis powers Notch cancer biotech Ayala to $30M series B
© 2026 Israel Biotech Fund • Built with GeneratePress